Advertisement

Current Infectious Disease Reports

, Volume 15, Issue 3, pp 242–250 | Cite as

Treatment and Prevention of Rotavirus Infection in Children

  • Penelope H. DennehyEmail author
Pediatric Infectious Diseases (I Brook, Section Editor)

Abstract

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. No antiviral therapy is available. Treatment of rotavirus gastroenteritis is limited to rehydration therapy. Recently, therapies, such as probiotics, have been developed as adjuncts to rehydration therapy. Two effective rotavirus vaccines are available and recommended for routine immunization of all infants. These vaccines have been introduced in both developed and developing countries. As rotavirus vaccines are implemented, studies that assess health impact, indirect benefits, and strain changes after the introduction of rotavirus vaccine have been reported. In the United States, rotavirus vaccination has led to dramatic drops in severe rotavirus-related hospitalizations and has reduced emergency room visits. Herd immunity has also been noted after routine rotavirus immunization. There have been no significant strain shifts or escape mutants noted since the introduction of rotavirus vaccines.

Keywords

Rotavirus Rotavirus vaccine Rotavirus gastroenteritis Rotavirus surveillance 

Notes

Acknowledgements

Dr. Dennehy is currently receiving a research grant from Merck and Company and previously had received research grants from Merck and GlaxoSmithKline Biologicals.

Conflict of Interest

Dr. P. Dennehy’s institution has received grant support from Merck and GlaxoSmithKline.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Fischer TK, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J Infect Dis. 2007;195(8):1117–25.Google Scholar
  3. 3.
    Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics. 2006;117(6):1887–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009;58(RR-2):1–25.PubMedGoogle Scholar
  5. 5.
    King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003;52(RR-16):1–16.PubMedGoogle Scholar
  6. 6.
    Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25(1):18–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Szajewska H, Dziechciarz P. Gastrointestinal infections in the pediatric population. Curr Opin Gastroenterol. 2010;26(1):36–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–153.PubMedCrossRefGoogle Scholar
  9. 9.
    Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet. 2006;368(9530):124–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther. 2006;24(10):1423–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis. 2009;13(4):518–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Szajewska H, Ruszczynski M, Chmielewska A, Wieczorek J. Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther. 2007;26(6):807–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Fedorowicz Z, Alhashimi D, Alhashimi H. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007;26(7):1086. author reply 1087.PubMedCrossRefGoogle Scholar
  14. 14.
    Szajewska H, Gieruszczak-Bialek D, Dylag M. Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children. Aliment Pharmacol Ther. 2007;25(4):393–400.PubMedCrossRefGoogle Scholar
  15. 15.
    World Health Organization. Rotavirus vaccines:an update. Wkly Epidemiol Rec. 2009;84(50):533–40.Google Scholar
  16. 16.
    Committee on Infectious Diseases of the American Academy of Pediatrics. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics. 2009;123(5):1412–20.CrossRefGoogle Scholar
  17. 17.
    •• Soares-Weiser K, Maclehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012;2:CD008521. This Cochrane systematic review evaluated rotavirus vaccines approved for use for preventing rotavirus diarrhea. Secondary objectives were to evaluate the efficacy of rotavirus vaccines on all-cause diarrhea, hospital admission, death, and safety profiles. The review found that RV1 and RV5 vaccines are effective in preventing rotavirus diarrhea.PubMedGoogle Scholar
  18. 18.
    • Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061–6. Although this study found no overall increase in intussusception following receipt of rotavirus vaccine, there was some evidence of an elevated risk following the first dose of both vaccines.PubMedCrossRefGoogle Scholar
  19. 19.
    • Patel MM, Lopez-Collada VR, Bulhoes MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283–92. An increased risk of intussusception after the first dose of RV1 was identified among infants in Mexico. No significant risk was found after the first dose among infants in Brazil.PubMedCrossRefGoogle Scholar
  20. 20.
    • Velazquez FR, Colindres RE, Grajales C, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J. 2012;31(7):736–44. This is the largest surveillance study for intussusception after rotavirus vaccination to date. A temporal increase in the risk for intussusception was seen within 7 days of administration of the first vaccine dose.PubMedCrossRefGoogle Scholar
  21. 21.
    Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012;307(6):598–604.PubMedCrossRefGoogle Scholar
  22. 22.
    Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J. 2012;31(3):292–6.PubMedCrossRefGoogle Scholar
  23. 23.
    •• Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD. Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009. J Infect Dis. 2012;206(1):41–8. This study examined age-specific trends in population-level intussusception hospitalization rates before (2000–2005) and after (2007–2009) rotavirus vaccine introduction among infants in 26 U.S. states comprising 75 % of the birth cohort and found, following rotavirus vaccine introduction, a small increase in intussusception rates was seen among U.S. infants 8–11 weeks of age.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Desai R, Cortese MM, Meltzer MI, et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J. 2013;32(1):1–7. The authors assumed a risk similar to international settings and compared potential vaccine-associated intussusception cases with benefits of prevention of rotavirus gastroenteritis by a fully implemented U.S. rotavirus vaccine program. They found that if an intussusception risk similar to that seen internationally exists in the United States, it is substantially exceeded by the benefits of rotavirus disease burden averted by vaccination.PubMedCrossRefGoogle Scholar
  25. 25.
    Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;84(12):6033–40.PubMedCrossRefGoogle Scholar
  26. 26.
    McClenahan SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine. 2011;29(29–30):4745–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Dore DD, Turnbull BR, Seeger JD. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiol Drug Saf. 2012;21(4):415–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Payne DC, Humiston S, Opel D, et al. A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of Porcine circovirus. BMC Pediatr. 2011;11:83.PubMedCrossRefGoogle Scholar
  29. 29.
    • Desai R, Lopman BA, Shimshoni Y, Harris JP, Patel MM, Parashar UD. Use of Internet search data to monitor impact of rotavirus vaccination in the United States. Clin Infect Dis. 2012;54(9):e115–118. Google-based Internet query share (IQS) for rotavirus search terms correlated well with U.S. rotavirus laboratory detections from 2004 to 2010 capturing the reduction observed during postvaccine years (2008–2010). The authors conclude that IQS analysis could become an inexpensive and reliable supplement for monitoring the impact of rotavirus vaccination in the United States.PubMedCrossRefGoogle Scholar
  30. 30.
    Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125(2):e199–207.PubMedCrossRefGoogle Scholar
  31. 31.
    Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J. 2010;29(12):1133–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Desai SN, Esposito DB, Shapiro ED, Dennehy PH, Vazquez M. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine. 2010;28(47):7501–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Eberly MD, Gorman GH, Eide MB, Olsen CH, Rajnik M. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine. 2011;29(4):650–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Guh AY, Hadler JL. Use of the state immunization information system to assess rotavirus vaccine effectiveness in Connecticut, 2006-2008. Vaccine. 2011;29(37):6155–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128(2):e267–275.PubMedCrossRefGoogle Scholar
  36. 36.
    Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics. 2010;125(2):e208–213.PubMedCrossRefGoogle Scholar
  37. 37.
    Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. 2010;29(10):957–63.PubMedCrossRefGoogle Scholar
  38. 38.
    Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics. 2010;126(1):e40–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Chang HG, Smith PF, Tserenpuntsag B, Markey K, Parashar U, Morse DL. Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine. 2010;28(3):754–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Clark HF, Lawley D, Matthijnssens J, DiNubile MJ, Hodinka RL. Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era. Pediatr Infect Dis J. 2010;29(8):699–702.PubMedCrossRefGoogle Scholar
  41. 41.
    • Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med. 2011;365(12):1108–17. This article notes that diarrhea-associated health-care utilization and medical expenditures for children have decreased substantially since the introduction of rotavirus vaccine in the United States.PubMedCrossRefGoogle Scholar
  42. 42.
    Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis. 2010;201(11):1617–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Custodio H, Masnita-Iusan C, Wludyka P, Rathore MH. Change in rotavirus epidemiology in northeast Florida after the introduction of rotavirus vaccine. Pediatr Infect Dis J. 2010;29(8):766–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Desai R, Curns AT, Steiner CA, Tate JE, Patel MM, Parashar UD. All-cause gastroenteritis and rotavirus-coded hospitalizations among US children, 2000-2009. Clin Infect Dis. 2012;55(4):e28–34.PubMedCrossRefGoogle Scholar
  45. 45.
    Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 2011;53(3):245–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Staat MA, Rice MA, Donauer S, et al. Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J. 2010;29(12):1083–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Williams DJ, Edwards KM, Payne DC, Manning J, Parashar UD, Lopman BA. Decline in gastroenteritis-related triage calls after rotavirus vaccine licensure. Pediatrics. 2012;130(4):e872–878.PubMedCrossRefGoogle Scholar
  48. 48.
    Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124(2):465–71.PubMedCrossRefGoogle Scholar
  49. 49.
    • Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J. 2011;30(1 Suppl):S30–34. This study reports that rotavirus activity was substantially diminished during the 2009–2010 rotavirus season, as compared with the prevaccine baseline and the two previous postvaccine introduction seasons. These sustained declines over three rotavirus seasons reaffirm the health benefits of the U.S. rotavirus vaccination program..PubMedGoogle Scholar
  50. 50.
    Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204(7):980–6.PubMedCrossRefGoogle Scholar
  51. 51.
    • Glass RI. Unexpected benefits of rotavirus vaccination in the United States. J Infect Dis. 2011;204(7):975–7. This commentary discusses the surprises about the epidemiology of disease revealed by the rotavirus vaccine program in the United States. including the herd effect of the vaccination program, that rotavirus is a greater than anticipated cause of gastroenteritis in older children and adults and that young children may be the source of infections in older children and adults..PubMedCrossRefGoogle Scholar
  52. 52.
    Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33.PubMedCrossRefGoogle Scholar
  53. 53.
    Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Vesikari T, Itzler R, Karvonen A, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 2009;28(2):345–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Turcios RM, Curns AT, Holman RC, et al. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Pediatr Infect Dis J. 2006;25(5):451–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Curns AT, Panozzo CA, Tate JE, et al. Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J. 2011;30(1 Suppl):S54–55.PubMedGoogle Scholar
  57. 57.
    • Banyai K, Laszlo B, Duque J, et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine. 2012;30 Suppl 1:A122–130. This study provides the most comprehensive, up-to-date information on rotavirus strain surveillance in the pre-rotavirus-vaccine era and will provide useful background to examine the impact of rotavirus vaccine introduction on future strain prevalence.PubMedCrossRefGoogle Scholar
  58. 58.
    Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–14.PubMedCrossRefGoogle Scholar
  60. 60.
    Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615–23.PubMedCrossRefGoogle Scholar
  61. 61.
    • Breiman RF, Zaman K, Armah G, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30 Suppl 1:A24–29. This analysis combines data from the five sites that strengthens the precision of vaccine efficacy estimates and reveals rising vaccine efficacy with increased rotavirus gastroenteritis severity. PubMedCrossRefGoogle Scholar
  62. 62.
    Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010;201(3):363–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J. 2011;30(5):396–401.PubMedCrossRefGoogle Scholar
  64. 64.
    Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis. 2011;52(2):191–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics. 2010;126(3):e506–512.PubMedCrossRefGoogle Scholar
  66. 66.
    Yen C, Figueroa JR, Uribe ES, et al. Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P[4] Rotavirus Strain in Mexico. J Infect Dis. 2011;204(5):783–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Justino MC, Araujo EC, van Doorn LJ, et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Mem Inst Oswaldo Cruz. 2012;107(7):846–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Carvalho-Costa FA, Volotao Ede M, de Assis RM, et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr Infect Dis J. 2011;30(1 Suppl):S35–41.PubMedGoogle Scholar
  69. 69.
    Hull JJ, Teel EN, Kerin TK, et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J. 2011;30(1 Suppl):S42–47.PubMedGoogle Scholar
  70. 70.
    Kirkwood CD, Boniface K, Barnes GL, Bishop RF. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr Infect Dis J. 2011;30(1 Suppl):S48–53.PubMedGoogle Scholar
  71. 71.
    Pitzer VE, Patel MM, Lopman BA, Viboud C, Parashar UD, Grenfell BT. Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci U S A. 2011;108(48):19353–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Boom JA, Sahni LC, Payne DC, et al. Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis. 2012;206(8):1275–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Donato CM, Ch'ng LS, Boniface KF, et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J Infect Dis. 2012;206(3):377–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Pediatric Infectious DiseasesHasbro Children’s HospitalProvidenceUSA
  2. 2.Department of PediatricsThe Alpert Medical School of Brown UniversityProvidenceUSA

Personalised recommendations